Arkolith/Insider Trading/NVCT/Form 4

Bentsur Ron

Chairman & CEO, Director, 10% OwnerNuvectis Pharma, Inc. (NVCT) · full profile →Form 4 · filed Dec 26, 2024
Net Buying
Open-Market Buys
$21K
Open-Market Sells
$0
Net Open-Market Flow
$21K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 24, 2024Buy(P)5K$4.65$21K3.3M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-24-131541) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML